1. Home
  2. BLFY vs TLSI Comparison

BLFY vs TLSI Comparison

Compare BLFY & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blue Foundry Bancorp

BLFY

Blue Foundry Bancorp

HOLD

Current Price

$13.21

Market Cap

298.3M

Sector

Finance

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$3.16

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLFY
TLSI
Founded
1939
2010
Country
United States
United States
Employees
N/A
102
Industry
Commercial Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.3M
270.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BLFY
TLSI
Price
$13.21
$3.16
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
699.9K
754.8K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
7.27
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.85
$35.45
Revenue Next Year
$20.18
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.61
$2.20
52 Week High
$14.74
$7.95

Technical Indicators

Market Signals
Indicator
BLFY
TLSI
Relative Strength Index (RSI) 54.31 41.31
Support Level $12.37 $2.20
Resistance Level $13.55 $5.41
Average True Range (ATR) 0.32 0.30
MACD 0.05 0.03
Stochastic Oscillator 95.05 50.96

Price Performance

Historical Comparison
BLFY
TLSI

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: